期刊
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
卷 38, 期 8, 页码 1500-1508出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/IAE.0000000000001753
关键词
age-related macular degeneration; anti-vascular endothelial growth factor; choroidal neovascularization; long-term outcomes; aflibercept; ranibizumab; bevacizumab; visual acuity; tachyphylaxis; geographic atrophy
资金
- Alcon
- Regeneron
- Genentech
Purpose: To summarize the findings of long-term outcomes of anti-vascular endothelial growth factor (VEGF) therapy (>= 36 months) in patients with exudative age-related macular degeneration. Methods: Studies reporting long-term outcomes (>= 36 months) of anti-VEGF therapy (n = 11) were identified and analyzed for changes in visual acuity (VA), optical coherence tomography, and safety findings. Results: Six prospective extension studies of Phase 3 clinical trials and five retrospective evaluation studies were identified. The largest improvements in VA with anti-VEGF treatment were found in Years 1 to 2 after treatment initiation. In five studies, VA ultimately declined below patients' pretreatment initial baseline; in three studies, VA ultimately returned to patients' baseline; in three studies, VA decreased but ultimately remained improved over patients' baseline. There was a trend demonstrating that a higher frequency of intravitreous injections showed a better maintenance in VA. Rates of adverse events were similar to previous registration studies of anti-VEGF drugs. Conclusion: The body of evidence to date regarding long-term anti-VEGF treatment indicates a variable course at greater than 36 months follow-up and seems to be dependent on the treatment protocol. Consistent dosing with fluid-free interval is suggested to maintain VA gains in patients with exudative age-related macular degeneration. There is no evidence suggesting that there are additional adverse events from long-term anti-VEGF use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据